Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Debt (2020 - 2025)

Historic Non-Current Debt for Zevra Therapeutics (ZVRA) over the last 8 years, with Q3 2025 value amounting to $61.3 million.

  • Zevra Therapeutics' Non-Current Debt rose 408.46% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.3 million, marking a year-over-year increase of 408.46%. This contributed to the annual value of $59.5 million for FY2024, which is 107457.56% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Non-Current Debt stood at $61.3 million, which was up 408.46% from $60.7 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Non-Current Debt registered a high of $61.3 million during Q3 2025, and its lowest value of $98000.0 during Q1 2021.
  • Its 5-year average for Non-Current Debt is $33.7 million, with a median of $37.9 million in 2024.
  • As far as peak fluctuations go, Zevra Therapeutics' Non-Current Debt plummeted by 6042.19% in 2023, and later skyrocketed by 107457.56% in 2024.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Non-Current Debt stood at $98000.0 in 2021, then skyrocketed by 12961.22% to $12.8 million in 2022, then plummeted by 60.42% to $5.1 million in 2023, then skyrocketed by 1074.58% to $59.5 million in 2024, then rose by 3.04% to $61.3 million in 2025.
  • Its Non-Current Debt stands at $61.3 million for Q3 2025, versus $60.7 million for Q2 2025 and $60.1 million for Q1 2025.